Advertisement


Matthew H.G. Katz, MD, on Pancreatic Cancer: Preoperative mFOLFIRINOX for Resectable Disease

2021 Gastrointestinal Cancers Symposium

Advertisement

Matthew H.G. Katz, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the Alliance A021501 study, which showed that administering mFOLFIRINOX before surgery was associated with a favorable overall survival rate relative to historical data in patients with borderline resectable adenocarcinoma of the pancreas (Abstract 377).



Related Videos

Hepatobiliary Cancer

Milind M. Javle, MD, on Cholangiocarcinoma: Treatment With Infigratinib

Milind M. Javle, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study results showing that the novel tyrosine kinase inhibitor infigratinib may prove to be effective in treating patients with advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement (Abstract 265).

Colorectal Cancer

Tenna V. Henriksen, PhD Candidate, on Colorectal Cancer: Circulating Tumor DNA Analysis to Improve Treatment

Tenna V. Henriksen, PhD Candidate, of Aarhus University, discusses her findings on how circulating tumor DNA may help assess recurrence risk and the benefit of adjuvant therapy, and more quickly detect early relapse after treatment in patients with colorectal cancer (Abstract 11).

Solid Tumors
Immunotherapy

Thierry André, MD, on Mismatch Repair–Deficient Solid Cancers: Safety and Efficacy of Dostarlimab

Thierry André, MD, of Hôpital Saint-Antoine, discusses results from the GARNET study, which showed that dostarlimab, an anti–PD-1 antibody, demonstrated durable antitumor activity in patients with mismatch repair–deficient colorectal and noncolorectal solid tumors. No new safety signals were detected, and most treatment-related adverse events were of a low grade (Abstract 9).

Neuroendocrine Tumors

Rocio Garcia-Carbonero, MD, on Treating Neuroendocrine Tumors of Nonpancreatic Origin With Octreotide Acetate and Axitinib

Rocio Garcia-Carbonero, MD, of Hospital Universitario 12 De Octubre, discusses results of the phase II/III AXINET trial, which showed that axitinib plus long-acting release octreotide improved overall response compared with placebo and octreotide in patients with advanced grade 1 or 2 extrapancreatic neuroendocrine tumors. However, no significant improvement in progression-free survival was observed (Abstract 360).

Gastrointestinal Cancer
Issues in Oncology

Afsaneh Barzi, MD, PhD, on Disparities in Access to Screening and Treatment of GI Cancers

Afsaneh Barzi, MD, PhD, of the City of Hope Comprehensive Cancer Center and the University of Southern California, discusses reasons for the incomplete understanding of the molecular landscape of minority patients with cancer, lack of screening chief among them. This underrepresentation, Dr. Barzi says, is more marked in gastrointestinal malignancies than other solid tumors, and she recommends ways to improve the outlook.

Advertisement

Advertisement



Advertisement